↓ Cooling
Business
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly sues six firms to shut down a black‑market trade in its experimental obesity drug retatrutide.
Eli Lilly
10 independently sourced, verified trend briefs about this subject.
What this topic page includes
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 2 news categories, from Jun 25, 2026 through Aug 12, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
◼ Archived
Business
🔮 holds ✓
Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide
Eli Lilly is planning a Q1 2027 FDA application for retatrutide following new data on weight loss and A1C improvements.
◼ Archived
Business
🔮 holds ✓
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of false and misleading advertising regarding weight-loss drug efficacy.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company used deceptive and false advertising regarding GLP-1 weight-loss medications.
◼ Archived
Business
🔮 fades ✓
Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly is reportedly nearing an acquisition of the psychedelic drugmaker AtaiBeckley, triggering significant movement in the company's share price.
◼ Archived
Business
🔮 holds ✓
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback
Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.
◼ Archived
Business
🔮 holds ✗
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs
◼ Archived
Business
🔮 holds ✗
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
The FDA has launched a new initiative to accelerate the review process for new pharmaceutical manufacturing facilities.
◼ Archived
Business
🔮 holds ✗
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
Eli Lilly shares surge following a CHMP recommendation for Jaypirca's EU approval to treat chronic lymphocytic leukemia.
◼ Archived
Health
🔮 holds ✗
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
Eli Lilly's CEO outlines the transformative potential of GLP-1s as new oral weight-loss medications enter development.